>>> For the latest QIDP list, please click HERE <<<
Since our last QIDP blog from April 8, 2015, several new drugs have made the list which now includes 41 compounds. Below a table which includes compound, sponsor and development stage (Phase). It also indicates whether a drug has been the topic of a more detailed write-up here in our blog pages. As before, the table is searchable.
This is a snapshot of a dynamic situation. If I made a mistake or omitted a drug which should have been included, please leave me a comment.
[table id=18 /]
Here some summary statistics which may be of interest:
- 33/43 drugs have a systemic mode of action:
- 29/33 are antibacterials, 4/33 are antifungals
- CONGRATULATIONS: 7/43 drugs have been approved in the US by FDA:
- long-acting glyco-(lipo-)peptides Orbactiv and Dalvance
- B-lactam/B-lactamase inhibitors Avycaz and Zerbaxa
- Sivextro and re-formulated Minocin
- The excellent new azole antifungal, Cresemba
- 5/43 drugs are old antibiotics (aminoglycosides, ciprofloxacin) formulated for aerosol pulmonary delivery
- 3/43 drugs are specifically active against Clostridium difficile infection
- 2/43 drugs are developed for topical use only
- 19/43 drugs are systemically active andcurrently in Phase 2 or 3 of development:
- 5/19 are fluoroquinolones, pursuing ABSSSI and MRSA indications
- 2/19 are antifungals: the azole SYM-1219, and the glucan synthase inhibitor SCY-078
- Only 4/19 are truly innovative NCEs, with new class potential:
- pleuromutilin BC-3781
- anti-pseudomonas drug POL-7080
- non-echinocandin SCY-078
- defensin-mimetic brilacidin
Link to this post!